Background-Integrated guidelines on cardiovascular health and risk reduction in children issued in 2011 newly recommended universal screening for dyslipidemia in children at 9 to 11 years and 17 to 21 years. Methods and Results-We determined the frequency and results of lipid testing in 301 080 children and adolescents aged 3 to 19 enrolled in 3 large US health systems in 2007 to 2010 before the 2011 guidelines were issued. Overall, 9.8% of the study population was tested for lipids. The proportion tested varied by body mass index percentile (5.9% of normal weight, 10.8% of overweight, and 26.9% of obese children) and age (8.9% of 9-to 11-year olds and 24.3% of 17-to 19-year olds). In normal weight individuals, 2.8% of 9-to 11-year olds and 22.0% of 17-to 19-year olds were tested. In multivariable models, age and body mass index category remained strongly associated with lipid testing. Sex, race, ethnicity, and blood pressure were weakly associated with testing. Abnormal lipid levels were found in 8.6% for total cholesterol, 22.5% for high-density lipoprotein-cholesterol, 12.0% for non-high-density lipoprotein-cholesterol, 8.0% for low-density lipoprotein-cholesterol, and 21% for triglycerides (age, 10-19 years). There was a strong and graded association of abnormal lipid levels with body mass index, particularly for high-density lipoprotein-cholesterol and triglycerides (2-to 6-fold higher odds ratio in obese when compared with that in normal weight children). Conclusions-Lipid screening was uncommon in 9-to 11-year olds and was performed in a minority of 17-to 19-year olds during 2007 to 2010. These data serve as a benchmark for assessing change in practice patterns after the new recommendations for pediatric lipid screening and management. (Circ Cardiovasc Qual Outcomes. 2014;7:718-726.)
A bnormal serum lipid levels in childhood are associated with dyslipidemia in adulthood and with the onset and severity of atherosclerosis in adolescence and young adulthood. [1] [2] [3] [4] [5] [6] Concern about the adverse effects of dyslipidemia on cardiovascular risk in the US population has been heightened by the increasing prevalence of overweight and obesity in children. 7, 8 In new guidelines sponsored by National Heart, Lung, and Blood Institute and endorsed by the American Academy of Pediatrics in 2011, the Expert Panel on Integrated Pediatric Guideline for Cardiovascular Health and Risk Reduction in Children and Adolescents concluded that there is sufficient evidence to support early identification of dyslipidemia and recommended universal screening for dyslipidemia in children at the age of 9 to 11 years and again at the age 17 to 21 years. 9 The expert panel recommendations contrast with the most recent recommendations of the US Preventive Services Task Force on this topic in 2007, which rated the evidence as insufficient to recommend for or against routine screening for lipid disorders in children or young adults age ≤20 years. 10 Other groups have recommended selective screening based on family history of premature heart disease or hypercholesterolemia or the presence of other risk factors, 10, 11 but the expert panel pointed out that such screening has not been proven to be effective and misses large numbers of children with dyslipidemia. 12 However, critics of the expert panel recommendations have raised concerns about the low predictive value of childhood lipid screening, adverse psychological effects of labeling, the unknown safety of lifelong statin treatment, the long-term costs, and lack of outcome data. [13] [14] [15] [16] Given the controversy surrounding the varying expert recommendations, additional data on preguideline pediatric lipid screening practices are needed to inform assessment of the effect of the new recommendations on identification of clinically significant dyslipidemia in children and adolescents. The present study used electronic data from 3 major US health systems to describe lipid screening from 2007 to 2010 in children and adolescents aged 3 to 19 years and to describe the proportion of abnormal test results. These data can serve as a benchmark for future studies examining changes in community practice in screening for dyslipidemia during childhood.
Methods

Study Setting and Population
This is an analysis of data from a retrospective cohort study conducted in 3 large integrated healthcare delivery systems: HealthPartners of Minnesota, Kaiser Permanente Colorado, and Kaiser Permanente Northern California (KPNC). The 3 participating study sites use the EpiCare electronic health record system (Verona, WI). The electronic health record captures enrollment and demographic data, encounter data including International Classification of Diseases-Ninth Revision-Clinical Modification diagnosis codes, prescribed medications, laboratory test results, and vital signs. The human subjects review board at HealthPartners approved the study protocol, and individual written consent was not required. Kaiser Permanente Colorado and KPNC ceded human subjects oversight to HealthPartners.
The cohort was established primarily to study pediatric hypertension and obesity. 17, 18 The study population included 363 318 children and adolescents aged 3 to 19 years with ≥1 visit during the study period from January 1, 2007, to December 31, 2010. Of these, 306 643 (84%) had an eligible blood pressure (BP) reading during the study period, defined as a BP measured in an outpatient setting with a corresponding height measurement taken within 90 days before or after the BP measurement. At HealthPartners and Kaiser Permanente Colorado, all subjects from 2007 to 2010 were eligible for study inclusion. The study population at KPNC consisted of a 50% sample of subjects from 2007 to 2010 who were seen in 3 KPNC subregions with early electronic health record implementation. Follow-up within the cohort began on the date of their first eligible BP reading and ended when health plan enrollment ended or December 31, 2010, whichever occurred sooner.
Because these analyses were designed to examine patterns of lipid screening in the general pediatric population, we excluded 3474 patients with dyslipidemia or conditions associated with dyslipidemia for which testing is recommended. We used International Classification of Diseases-Ninth Revision, Clinical Modification codes to identify patients with the following exclusion diagnoses or procedures based
WHAT IS KNOWN
• In addition to selective screening of children based on family history and risk factors, such as overweight, guidelines issued in 2011 now recommend universal lipid screening at the age 9 to 11 and 17 to 21 years. • Little is known about lipid screening of children and adolescents in community practice before the 2011 guidelines
WHAT THE STUDY ADDS
• In 3 major US health systems lipid screening was done in 8.9% of 9-to 11-year olds and 24.3% of 17to 19-year olds during 2007 to 2010. • The proportion of children screened increased with age and body mass index although a minority of overweight and obese children were screened in all age groups. • Although abnormal lipid values were more likely to be found in children with elevated body mass index, among children with body mass index <85th percentile abnormal lipid levels were found in 6.7% for total cholesterol, 12.6% for high-density lipoproteincholesterol, and 6.9% for non-high-density lipoprotein-cholesterol. This suggests that more children will be newly identified as having dyslipidemia with universal pediatric lipid screening. We further excluded 216 children whose initial laboratory testing did not include a total cholesterol measurement. The final analytic sample consisted of 301 080 children.
Analytic Methods
We calculated the proportion of children who had ≥1 measurement of total cholesterol, and within this subgroup the proportion of children who had ≥1 measurement of high-density lipoprotein-cholesterol (HDL-C). The proportion of children with a non-HDL-C measurement was calculated if the total cholesterol and HDL-C measurements occurred on the same day. The proportion of children with a low-density lipoprotein-cholesterol (LDL-C) was calculated if total cholesterol, HDL-C, and fasting triglycerides were measured on the same day or there was a direct measurement of LDL-C. At KPNC, we could not determine from electronic health record data whether triglyceride measurements were performed in the fasting state; therefore, in our primary analyses, we excluded calculated LDL-C and triglyceride measurements from KPNC. In secondary analyses, we included nonfasting triglycerides measurements and calculated LDL-C measurements from all sites. We examined the proportion of children with lipid testing stratified by age at initial testing (3-5, 6-8, 9-11, 12-16 , and 17-19 years), body mass index (BMI) percentile (<85th, 85 to <95th, and ≥95th), and BP percentile (greater of systolic or diastolic BP, <90th, 90 to <95th, and ≥95th) measured closest to the date of lipid testing or at the midpoint of follow-up for children without lipid testing. We also stratified by sex, race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, Asian, other race, and unknown race/ethnicity), insurance type (commercial, government, other [high-deductible, private pay, or self-funded], or unknown), and whether the child had ≥1 well-child visit during the study period.
We calculated the mean value and SD of lipid test results for the first recorded total cholesterol, HDL-C, non-HDL-C, fasting triglyceride, and LDL-C (estimated using the Friedewald formula 19 or directly measured). Using the first lipid test(s) recorded (total cholesterol, total cholesterol/HDL-C, or fasting lipid panel/direct LDL-C), we classified 
Results
Of the 301 080 children who met the study eligibility criteria, 50.1% were boys and 49.9% were girls ( Overall, 29 360 (9.8%) of the study population was tested for lipids with measurement of at least total cholesterol ( Table 1 ). The proportion of children and adolescents tested increased markedly with age. The proportion tested varied by BMI percentile (5.9% of normal weight, 10.8% of overweight, and 26.9% of obese children) and there was also a greater likelihood of lipid testing with higher BP percentile category. There was relatively little variation in lipid testing by insurance type, but the 16% of children who did not have a wellchild visit were less likely to be tested. After multivariable adjustment, age and BMI category remained strongly associated with lipid testing, whereas female sex, race, Hispanic ethnicity, Asian race, and BP percentile category were more weakly associated with testing (Table 1) . Although children with commercial and government insurance were equally likely to be tested, children without well-child visits were much less likely to be tested even after adjustment for age and BMI (hazard ratio, 0.33; 95% confidence interval, 0.31-0.34).
In normal weight children, testing rates were 0.5% for 3-to 5-year olds, 1.6% for 6-to 8-year olds, 2.8% for 9-to 11year olds, 7.1% for 12-to 16-year olds, and 22.0% for 17-to 19-year olds (Tables 2-4). Among all age groups, both sexes, and all racial/ethnic groups, the proportion tested was progressively higher in overweight and obese children. The highest screening rates were in obese Hispanic youth aged 12 to 16 years (41.9%), followed by Asian/Pacific Islanders aged 12 to 16 years (37.9%). Obese non-Hispanic whites aged 17 to 19 years were more likely to be screened than younger teens (34.4% versus 30.9%, respectively). Girls were more likely to be screened across all ethnic and BMI categories, with the highest overall screening rate in obese Hispanic girls aged 12 to 16 years (45.6%). Those tested for total cholesterol usually had an HDL-C done on the same day (86.7%), allowing calculation of non-HDL-C (Table 5 ). Fewer children had testing for fasting triglycerides (28.0%) or assessment of LDL-C (33.2%) as part of their initial evaluation, although when measurements with unknown duration of fasting were included, most children were also tested for triglycerides (76.9%) and LDL-C (80.3%, data not shown). Abnormal lipid levels were found in 8.6% of the cohort for total cholesterol, 22.5% for HDL-C, 12.0% for non-HDL-C, 8.0% for LDL-C, and 19% -38% for triglycerides, depending on age and sex ( Table 5 ). Thirty-two individuals (0.33%) had LDL-C≥190 mg/dL, of whom 10 had normal weight, 12 were overweight, and 10 were obese (data not shown).
Girls were less likely to have low levels of HDL-C than boys. Children aged 9 to 11 years had the highest proportion of abnormal non-HDL-C levels (14.4%) when compared with other age groups, and more Black children had lower levels (9.7%) than children of other races/ethnicities. There was a strong and graded association of abnormal lipid levels with BMI in the overweight and obese range, particularly for HDL-C and triglycerides. In multivariable models, the odds of abnormal lipid results were 2-to 6-fold higher in obese children when compared with those with normal weight ( Table 6 ). Asian and Black children were less likely to have low HDL-C levels, whereas Black and Hispanic children were less likely to have elevated total cholesterol and non-HDL-C, and Black children were markedly less likely to have elevated triglyceride levels. Mean results of lipid measurements by age, race/ethnicity, and BMI are shown in Table 7 .
Discussion
Our findings from this study in community-based healthcare systems demonstrate that during the period from 2007 to 2010, lipid screening was uncommon in 9-to 11-year-old children and was performed in less than one quarter of 17-to 19-year-old adolescents, both of the age groups targeted by the recent integrated guidelines for screening. Lipid screening was even relatively low in obese children at all ages, despite the ongoing pediatric recommendation for screening in this group during the period of this study. [20] [21] [22] Few data are available on contemporary lipid screening practices in children and adolescents, and no studies have reported data after publication of the recommendation for universal screening. A recent study from the National Ambulatory Medical Care Survey using data from 10 159 health maintenance visits among patients aged 2 to 19 years from 1995 to 2010 reported that lipid screening was performed at only 347 visits (3.4%; 95% confidence interval, 3.1%-3.8%) with little change over the period of observation. 23 However, that study lacked data on other risk factors that might have affected testing decisions and was thus unable to distinguish screening from indicated testing. Moreover, unlike our longitudinal study, that cross-sectional study was likely to have underestimated the proportion of youth being screened over time and at visits other than well-child visits. Our study population had a similar prevalence of overweight and obesity as has been reported for a representative sample of US children aged 2 to 19 years during 2007 to 2010 in the National Health and Nutrition Examination Surveys (NHANES). 7, 8 However, in contrast to NHANES, which reported lipid tests for all children in their sample regardless of BMI, our study population was more likely to be differentially screened based on BMI. Mean total cholesterol levels for each age and sex subgroup were similar to the national population-based data reported in NHANES, but HDL-C levels were consistently 3 to 6 mg/dL lower than national data from 2007 to 2010. 24 Triglyceride levels were generally 10 to 20 mg/dL higher than national data (with considerable variability by age, sex, and race/ethnicity). This pattern is expected given the observed higher rates of lipid testing in overweight and obese children, who have a greater likelihood of abnormal HDL-C and triglycerides. Consequently, non-HDL-C and LDL-C levels were also higher in our sample than in NHANES, except for adolescents aged 17 to 19 years. We observed other patterns as expected based on national data: total cholesterol and non-HDL-C peaked at the age of 9 to 11 years, decreased in early adolescence, and increased thereafter; HDL-C fell progressively with age in boys, whereas in girls it reached a nadir at the age of 9 to 11 years and increased in adolescence; black children had higher levels of HDL-C and markedly lower levels of triglycerides when compared with white and Hispanic children.
We found abnormal lipid levels in 8.6% of the cohort for total cholesterol, 22.5% for HDL-C, 12.0% for non-HDL-C, 8.0% for LDL-C, and 19% to 38% for triglycerides, depending on age and sex. Although the proportion of children with total cholesterol ≥200 mg/dL (8.6% versus 8.1%) and LDL-C≥130 mg/dL (8.0% versus 7.4%) did not differ substantially from the proportion in NHANES, we identified a higher proportion of children with HDL-C<40 mg/dL (22.5% versus 14.8%), non-HDL-C≥145 mg/dL (12.0% versus 10.%), and triglycerides ≥130 mg/dL (20.7% versus 12.4%). 24 Again, this is likely related to selective screening of overweight and obese children in our study settings during 2007 to 2010 as recommended by then-current guidelines. Therefore, because screening practices add universal screening in 9-to 11-year olds and 17-to 21-year olds to targeted screening of children in other age groups as recommended in new 2011 guidelines, 9 we anticipate that the proportion of children with abnormal levels of lipids will be lower than we observed in 2007 to 2010 but higher than in a random sample of the population, such as NHANES. However, the absolute numbers of children with abnormal test results requiring further evaluation and management is likely to increase. The 2011 guidelines state that children with non-HDL-C≥145 mg/dL or HDL-C<40 should be further evaluated with 2 subsequent fasting lipid panels, and subsequent management should be based on levels of LDL-C and triglycerides. Our data and NHANES data suggest that 11% to 14% of children will have non-HDL-C levels≥145 mg/dL, and additional children will have HDL<40 mg/dL. Thus, many individuals will be newly identified as having dyslipidemia and be recommended to receive additional diagnostic testing.
Although abnormal lipid values were more likely to be found in children with elevated BMI percentile, we found some normal weight children with a low level of HDL-C (12.6%) or a high level of non-HDL-C (6.9%). Thus, targeted screening for children with BMI above the 85th or 95th percentile would clearly miss some normal weight children with lipid abnormalities, including a small number of children with LDL-C levels compatible with familial hypercholesterolemia. Our study lacked data on family history, but others have found that using family history of premature cardiovascular disease or dyslipidemia also fails to detect a substantial proportion of children with abnormal lipids. 12 These results should be interpreted in light of several limitations of the study. First, we required a BP and height measurement, so this analysis does not include the 16% of enrolled children who received little or no care during the study period, as evidenced by not having ≥1 BP and height measurement. If these children had been included, screening rates would likely have been somewhat lower. Second, we included children in the analysis regardless of their duration of enrollment in the health system, so this may partly explain why 16% of children did not have a well-child visit. These children were much less likely to be screened even though they were receiving some health care. Third, the screening rates reflect only completed lipid tests and do not include tests that were ordered but not completed. Fourth, some children may have had a lipid screen before the start of the study period in 2007 and were appropriately not retested. For this reason, it is also possible that some test results we observed during 2007 to 2010 were follow-up tests for abnormal screening tests conducted before 2007. Finally, although we excluded children with clinical indications for lipid testing, family history of dyslipidemia and premature cardiovascular disease was not available in our electronic records. Therefore some children with normal BMI and no other apparent indication for testing may have been tested based on family history.
We conclude that in 2007 to 2010, lipid screening was uncommon in 9-to 11-year olds and was performed in a minority of 17-to 19-year olds. These data provide a useful benchmark for assessing change in practice patterns in large heath systems following the new recommendations for pediatric lipid screening and subsequent management. The costs of universal screening at the age 9 to 11 and 17 to 21 years and the effectiveness of this policy for identifying at-risk youth and lowering their risk of cardiovascular disease later in life will require further research.
